Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).
暂无分享,去创建一个
A. Bardia | D. Juric | L. Ellisen | L. Spring | S. Wander | J. Supko | S. Isakoff | B. Moy | K. Habin | N. Vidula | D. Micalizzi | E. Viscosi | Lauren Scarpetti | M. Beeler | D. Fitzgerald | E. Tripp | Rachel Hepp